Virtune AB (Publ)
Virtune AB (Publ) ("Virtune") has completed the rebalancing for December 2025 of its Virtune Stablecoin Index ETP
Virtune AB (Publ) ("Virtune") has completed the rebalancing for December 2025 of its Virtune Stablecoin Index ETP
Stockholm, January 7th, 2026 – Virtune today announces the completion of the first rebalancing for the Virtune Stablecoin Index ETP (SE0026821282), listed on Nasdaq Stockholm, Nasdaq Helsinki and Xetra.
In addition to the Virtune Stablecoin Index ETP, Virtune’s product portfolio includes:
Virtune Bitcoin ETP
Virtune Staked Ethereum ETP
Virtune XRP ETP
Virtune Staked Solana ETP
Virtune Staked Polkadot ETP
Virtune Crypto Altcoin Index ETP
Virtune Crypto Top 10 Index ETP
Virtune Litecoin ETP
Virtune Avalanche ETP
Virtune Chainlink ETP
Virtune Arbitrum ETP
Virtune Staked Polygon ETP
Virtune Staked Cardano ETP
Virtune Bitcoin Prime ETP
Virtune Stellar ETP
Virtune Staked NEAR ETP
Virtune Coinbase 50 Index ETP
Virtune Stablecoin Index ETP
Virtune Sui ETP
Virtune Bittensor ETP
Index allocation as of December 30th (before rebalancing):
Ethereum: 44.08%
XRP: 23.62%
Solana: 17.39%
Chainlink: 6.12%
Stellar: 5.66%
Aave: 3.13%
Index allocation as of December 30th (after rebalancing):
Ethereum: 41.84%
XRP: 23.79%
Solana: 18.53%
Chainlink: 6.56%
Stellar: 5.90%
Aave: 3.39%
The index is rebalanced quarterly to reflect market changes and ensure it continues to represent the most relevant and qualitative crypto assets. The rebalancing adjusts the weighting based on market capitalization and may involve removing or adding certain assets.
This rebalancing introduces no changes to the crypto assets included in the index.
The performance of Virtune Stablecoin Index ETP in December was +0.53%.
Virtune Stablecoin Index ETP is a physically backed Exchange Traded Product (ETP) designed to offer investors a simple, secure, and cost-effective way to gain exposure to the expanding stablecoin ecosystem. The product tracks a diversified index of digital assets that provide the infrastructure and rails making stablecoins possible and that stand to benefit from their growing adoption and use.
If you, as an (institutional) investor, are interested in meeting with Virtune to discuss the opportunities our ETPs offer for your asset management services or to learn more about Virtune and our ETPs, please do not hesitate to contact us at hello@virtune.com. You can also read more about Virtune and our ETPs at www.virtune.com and register your email address on our website to subscribe to our newsletters, which cover updates on Virtune's upcoming ETP launches and other news related to digital assets.
Press contact
Christopher Kock, CEO Virtune AB (Publ)
Christopher@virtune.com
+46 70 073 45 64
Virtune, headquartered in Stockholm, is a regulated Swedish digital asset manager and issuer of crypto exchange traded products on regulated European exchanges. With regulatory compliance, strategic collaborations with industry leaders and our proficient team, we empower investors on a global level to access innovative and sophisticated investment products that are aligned with the evolving landscape of the global crypto market.
Cryptocurrency investments are associated with high risk. Virtune does not provide investment advice. Investments are made at your own risk. Securities may increase or decrease in value, and there is no guarantee that you will recover your invested capital. Please read the prospectus, KID, terms at www.virtune.com.
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
NTR Holding A/S9.1.2026 09:37:54 CET | Press release
Nasdaq Copenhagen A/S godkender afnotering af NTR Holding A/S’ B-aktier
Alveus Therapeutics Inc9.1.2026 09:13:19 CET | Pressemeddelelse
Alveus Therapeutics annoncerer serie A-financiering på 160 mio. USD til næste generations behandlinger mod fedme og stofskiftesygdomme
Yacht Club de Monaco9.1.2026 09:05:00 CET | Press release
At the Yacht Club de Monaco a year of transition and innovation begins
Onco3R Therapeutics BV9.1.2026 09:00:00 CET | Press release
O3R-5671 Pharmacokinetic and Pharmacodynamic Data to be Presented at ECCO and Dosing in Final Cohort in First-in-human study initiated
Zealand Pharma9.1.2026 08:00:00 CET | Press release
Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom